Towards the development of an effective treatment for SCN1A-derived epilepsy

致力于开发 SCN1A 源性癫痫的有效治疗方法

基本信息

  • 批准号:
    9272959
  • 负责人:
  • 金额:
    $ 19.35万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2016
  • 资助国家:
    美国
  • 起止时间:
    2016-06-01 至 2019-05-31
  • 项目状态:
    已结题

项目摘要

PROJECT SUMMARY De novo loss-of-function mutations in the voltage-gated sodium channel SCN1A (encoding Nav1.1) are the main cause of Dravet syndrome (DS), a catastrophic early-life encephalopathy associated with prolonged and recurrent febrile seizures (FSs), treatment-resistant afebrile epilepsy, cognitive and behavioral deficits, and a 15-20% mortality rate. SCN1A mutations also lead to genetic epilepsy with febrile seizures plus (GEFS+), an inherited disorder characterized by early-life FSs and the development of a wide range of adult epilepsy subtypes. Current anti-epilepsy drugs often fail to provide adequate protection against the severe seizures and neuropsychiatric comorbidities that occur in patients with SCN1A mutations. Furthermore, almost a third of all epilepsy patients do not achieve adequate seizure control, highlighting the urgent need to develop multimodal treatments that can effectively mitigate the broad spectrum of clinical features associated with refractory epilepsies, while minimizing unwanted side effects. In this exploratory R21 proposal, we will test the hypothesis that Huperzine A (Hup A), a naturally occurring sesquiterpene Lycopodium alkaloid, will be efficacious in the treatment of DS. This hypothesis is based on the biological properties of Hup A, its demonstrated clinical safety, tolerability, ability to improve cognitive function, and our preliminary data. We will use heterozygous Scn1a knockout mice (a model of DS) to evaluate the potential of Hup A to increase seizure thresholds and prevent spontaneous seizure generation (Aim 1) and to ameliorate cognitive and behavioral deficits (Aim 2). This clinically relevant proposal could lay the foundation for the development of a novel therapy to treat SCN1A-derived epilepsies. Furthermore, since SCN1A mutations lead to reduced neuronal inhibition, which is a shared mechanism underlying many common forms of epilepsy, the outcome of this study may have important, broad implications for the treatment of refractory epilepsies.
项目总结 电压门控钠通道SCN1A(编码Nav1.1)的从头功能丧失突变是 德雷特综合征(DS)的主要原因,这是一种灾难性的早期脑病,与长期和 复发性热性癫痫(FSS)、难治性无热性癫痫、认知和行为障碍以及 死亡率为15%-20%。SCN1A突变也会导致遗传性癫痫伴热性惊厥(GEFS+),以及 以早期FSS和多种成人癫痫的发展为特征的遗传性疾病 子类型。目前的抗癫痫药物往往不能提供足够的保护,防止严重的癫痫发作和 发生在SCN1A突变患者中的神经精神共病。此外,几乎三分之一的人 癫痫患者没有实现足够的癫痫发作控制,突出了发展多模式的迫切需要 可有效缓解与难治性疾病相关的广泛临床特征的治疗方法 癫痫,同时将不良副作用降至最低。在这个探索性的R21提案中,我们将检验假设 石杉碱甲(Hup A)是一种天然的倍半萜石杉碱类生物碱,对糖尿病有明显的治疗作用。 DS的治疗。这一假设是基于Hup A的生物学特性,它证明了它的临床应用 安全性、耐受性、改善认知功能的能力,以及我们的初步数据。我们将使用杂合子 SCN1A基因敲除小鼠(DS模型)评估Hup A提高癫痫阈值和 预防自发性癫痫发作(目标1)和改善认知和行为缺陷(目标2)。 这一具有临床相关性的建议可能为开发一种新的治疗方法奠定基础。 SCN1A型癫痫。此外,由于SCN1A突变导致神经元抑制减少,这是 许多常见形式癫痫的共同机制,这项研究的结果可能有 对于难治性癫痫的治疗具有重要而广泛的意义。

项目成果

期刊论文数量(3)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Donepezil increases resistance to induced seizures in a mouse model of Dravet syndrome.
多奈哌齐可增加 Dravet 综合征小鼠模型对诱发癫痫发作的抵抗力。
Huperzine A Provides Robust and Sustained Protection against Induced Seizures in Scn1a Mutant Mice.
  • DOI:
    10.3389/fphar.2016.00357
  • 发表时间:
    2016
  • 期刊:
  • 影响因子:
    5.6
  • 作者:
    Wong JC;Dutton SB;Collins SD;Schachter S;Escayg A
  • 通讯作者:
    Escayg A
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Andrew P Escayg其他文献

Andrew P Escayg的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Andrew P Escayg', 18)}}的其他基金

SCN8A encephalopathy: disease mechanisms and treatment
SCN8A 脑病:疾病机制和治疗
  • 批准号:
    10586642
  • 财政年份:
    2023
  • 资助金额:
    $ 19.35万
  • 项目类别:
Exploring the role of GADD45A in Alzheimer's disease
探索 GADD45A 在阿尔茨海默病中的作用
  • 批准号:
    10373344
  • 财政年份:
    2022
  • 资助金额:
    $ 19.35万
  • 项目类别:
Exploring the role of oxytocin in the regulation of neuronal excitability
探索催产素在神经元兴奋性调节中的作用
  • 批准号:
    10593062
  • 财政年份:
    2021
  • 资助金额:
    $ 19.35万
  • 项目类别:
Exploring the role of oxytocin in the regulation of neuronal excitability
探索催产素在神经元兴奋性调节中的作用
  • 批准号:
    10397642
  • 财政年份:
    2021
  • 资助金额:
    $ 19.35万
  • 项目类别:
Exploring the range of seizure and behavioral phenotypes due to SCN8A mutations
探索 SCN8A 突变引起的癫痫发作和行为表型的范围
  • 批准号:
    9978424
  • 财政年份:
    2020
  • 资助金额:
    $ 19.35万
  • 项目类别:
Exploring reversible AChE inhibitors as a treatment for refractory epilepsies
探索可逆的 AChE 抑制剂治疗难治性癫痫
  • 批准号:
    9764633
  • 财政年份:
    2019
  • 资助金额:
    $ 19.35万
  • 项目类别:
N-terminal huntingtin and Huntington disease neuropathology
N 末端亨廷顿蛋白和亨廷顿病神经病理学
  • 批准号:
    10117290
  • 财政年份:
    2017
  • 资助金额:
    $ 19.35万
  • 项目类别:
Towards the development of an effective treatment for SCN1A-derived epilepsy
致力于开发 SCN1A 源性癫痫的有效治疗方法
  • 批准号:
    9195849
  • 财政年份:
    2016
  • 资助金额:
    $ 19.35万
  • 项目类别:
A novel target for the treatment of temporal lobe epilepsy
治疗颞叶癫痫的新靶点
  • 批准号:
    9087344
  • 财政年份:
    2015
  • 资助金额:
    $ 19.35万
  • 项目类别:
SCN1A dysfunction and neuropsychiatric comorbidities
SCN1A 功能障碍和神经精神合并症
  • 批准号:
    8702781
  • 财政年份:
    2014
  • 资助金额:
    $ 19.35万
  • 项目类别:

相似海外基金

Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
  • 批准号:
    MR/S03398X/2
  • 财政年份:
    2024
  • 资助金额:
    $ 19.35万
  • 项目类别:
    Fellowship
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
  • 批准号:
    2338423
  • 财政年份:
    2024
  • 资助金额:
    $ 19.35万
  • 项目类别:
    Continuing Grant
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
  • 批准号:
    EP/Y001486/1
  • 财政年份:
    2024
  • 资助金额:
    $ 19.35万
  • 项目类别:
    Research Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
  • 批准号:
    MR/X03657X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 19.35万
  • 项目类别:
    Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
  • 批准号:
    2348066
  • 财政年份:
    2024
  • 资助金额:
    $ 19.35万
  • 项目类别:
    Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
  • 批准号:
    AH/Z505481/1
  • 财政年份:
    2024
  • 资助金额:
    $ 19.35万
  • 项目类别:
    Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10107647
  • 财政年份:
    2024
  • 资助金额:
    $ 19.35万
  • 项目类别:
    EU-Funded
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
  • 批准号:
    2341402
  • 财政年份:
    2024
  • 资助金额:
    $ 19.35万
  • 项目类别:
    Standard Grant
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10106221
  • 财政年份:
    2024
  • 资助金额:
    $ 19.35万
  • 项目类别:
    EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
  • 批准号:
    AH/Z505341/1
  • 财政年份:
    2024
  • 资助金额:
    $ 19.35万
  • 项目类别:
    Research Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了